JPWO2020219868A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020219868A5
JPWO2020219868A5 JP2021562790A JP2021562790A JPWO2020219868A5 JP WO2020219868 A5 JPWO2020219868 A5 JP WO2020219868A5 JP 2021562790 A JP2021562790 A JP 2021562790A JP 2021562790 A JP2021562790 A JP 2021562790A JP WO2020219868 A5 JPWO2020219868 A5 JP WO2020219868A5
Authority
JP
Japan
Prior art keywords
seq
mab
amino acid
acid sequence
transgene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021562790A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530006A (ja
JP7672344B2 (ja
JP2022530006A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029802 external-priority patent/WO2020219868A1/en
Publication of JP2022530006A publication Critical patent/JP2022530006A/ja
Publication of JPWO2020219868A5 publication Critical patent/JPWO2020219868A5/ja
Publication of JP2022530006A5 publication Critical patent/JP2022530006A5/ja
Priority to JP2025070079A priority Critical patent/JP2025121920A/ja
Application granted granted Critical
Publication of JP7672344B2 publication Critical patent/JP7672344B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021562790A 2019-04-24 2020-04-24 完全ヒト翻訳後修飾抗体による治療剤 Active JP7672344B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025070079A JP2025121920A (ja) 2019-04-24 2025-04-22 完全ヒト翻訳後修飾抗体による治療剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962838165P 2019-04-24 2019-04-24
US62/838,165 2019-04-24
US202062967472P 2020-01-29 2020-01-29
US62/967,472 2020-01-29
PCT/US2020/029802 WO2020219868A1 (en) 2019-04-24 2020-04-24 Fully-human post-translationally modified antibody therapeutics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025070079A Division JP2025121920A (ja) 2019-04-24 2025-04-22 完全ヒト翻訳後修飾抗体による治療剤

Publications (4)

Publication Number Publication Date
JP2022530006A JP2022530006A (ja) 2022-06-27
JPWO2020219868A5 true JPWO2020219868A5 (https=) 2023-05-01
JP2022530006A5 JP2022530006A5 (https=) 2023-05-01
JP7672344B2 JP7672344B2 (ja) 2025-05-07

Family

ID=70861534

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021562790A Active JP7672344B2 (ja) 2019-04-24 2020-04-24 完全ヒト翻訳後修飾抗体による治療剤
JP2025070079A Pending JP2025121920A (ja) 2019-04-24 2025-04-22 完全ヒト翻訳後修飾抗体による治療剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025070079A Pending JP2025121920A (ja) 2019-04-24 2025-04-22 完全ヒト翻訳後修飾抗体による治療剤

Country Status (13)

Country Link
US (1) US20220195462A1 (https=)
EP (1) EP3959323A1 (https=)
JP (2) JP7672344B2 (https=)
KR (1) KR20220012231A (https=)
CN (1) CN114144197A (https=)
AU (1) AU2020262416A1 (https=)
BR (1) BR112021021156A2 (https=)
CA (1) CA3137284A1 (https=)
IL (1) IL287414A (https=)
MX (1) MX2021012867A (https=)
SG (1) SG11202111414RA (https=)
TW (1) TW202106708A (https=)
WO (1) WO2020219868A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
MX2020006435A (es) 2017-12-19 2021-02-09 Akouos Inc Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno.
US12290574B2 (en) 2018-08-24 2025-05-06 Spark Therapeutics, Inc. Optimized promoter sequences, intron-free expression constructs and methods of use
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
AR120898A1 (es) * 2019-12-26 2022-03-30 Univ Osaka Agente para tratar o prevenir neuromielitis óptica en fase aguda
CN114945385A (zh) * 2020-01-15 2022-08-26 国立大学法人大阪大学 痴呆症的预防或治疗剂
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
EP4213890A1 (en) * 2020-09-15 2023-07-26 RegenxBio Inc. Vectorized lanadelumab and administration thereof
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
WO2022120352A1 (en) * 2020-12-02 2022-06-09 Alector Llc Methods of use of anti-sortilin antibodies
CN116391041A (zh) * 2020-12-03 2023-07-04 江苏恒瑞医药股份有限公司 一种含抗结缔组织生长因子抗体的药物组合物
US20220186252A1 (en) * 2020-12-16 2022-06-16 Takeda Pharmaceutical Company Limited Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein
CN112646787A (zh) * 2020-12-29 2021-04-13 武汉生物工程学院 一种以痘苗病毒天坛株为载体的新冠疫苗及其构建方法
US20240092885A1 (en) * 2021-01-26 2024-03-21 Kriya Therapeutics, Inc. Vector constructs for delivery of nucleic acids encoding therapeutic anti-tnf antibodies and methods of using the same
CN114907485B (zh) * 2021-02-08 2024-04-26 浙江大学 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
AU2022235284A1 (en) * 2021-03-12 2023-10-05 Excepgen Inc. Systems and methods for protein expression
KR20240023127A (ko) * 2021-06-18 2024-02-20 이카로벡 리미티드 망막 장애
EP4384218A4 (en) * 2021-08-09 2025-11-05 Merck Patent Gmbh Proteins that uncouple T-lymphocyte-mediated tumor cytotoxicity from the release of pro-inflammatory cytokines
US20230374546A1 (en) * 2022-03-11 2023-11-23 Homology Medicines, Inc. Bidirectional dual promoter expression vectors and uses thereof
WO2023183623A1 (en) 2022-03-25 2023-09-28 Regenxbio Inc. Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
TW202404651A (zh) 2022-04-06 2024-02-01 美商銳進科斯生物股份有限公司 用於脈絡膜上投與之調配物諸如形成聚集體之調配物
CA3247507A1 (en) * 2022-04-06 2023-10-12 Regenxbio Inc. PHARMACEUTICAL COMPOSITION COMPRISING A RECOMMENDED ADENO-ASSOCIATED VIRUS (AAV) VECTOR WITH AN EXPRESSION CASSETTE ENCODED BY A TRANSGENE FOR SUPRACHOROID ADMINISTRATION
TW202345913A (zh) 2022-04-06 2023-12-01 美商銳進科斯生物股份有限公司 用於脈絡膜上投與之調配物諸如凝膠調配物
EP4518972A2 (en) * 2022-05-03 2025-03-12 RegenxBio Inc. Vectorized anti-complement antibodies and complement agents and administration thereof
CN117304307A (zh) * 2022-06-27 2023-12-29 上海鼎新基因科技有限公司 一种治疗新生血管相关眼底疾病的aav药物
WO2024003578A1 (en) * 2022-07-01 2024-01-04 The University Of Bristol Vector comprising a sequence encoding an anti-tnf antibody and an inflammation-inducible promoter
CN116716351B (zh) * 2023-03-30 2024-02-23 湖北天勤生物技术研究院有限公司 用于构建食蟹猴阿尔兹海默症模型的组合物及其应用和构建方法
AU2024271004A1 (en) * 2023-05-16 2026-01-15 Regenxbio Inc. Vectorized anti-complement antibodies and administration thereof
WO2025011508A1 (zh) * 2023-07-07 2025-01-16 深圳先进技术研究院 降低肿瘤内中性粒细胞水平的抗肿瘤细菌
WO2025049480A2 (en) * 2023-08-31 2025-03-06 Visgenx, Inc. Elovl2 constructs for gene therapy
WO2025104243A1 (en) * 2023-11-15 2025-05-22 Neurimmune Ag Anti-transthyretin antibody, compositions comprising said antibody and methods for treating or preventing transthyretin-mediated amyloidosis
CN120060370A (zh) * 2023-11-29 2025-05-30 上海科锐克医药科技有限公司 用于递送人vegf受体融合蛋白的基因递送载体及其应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ206195A3 (en) 1993-02-12 1996-04-17 Univ Leland Stanford Junior Controlled transcription of target genes and other biological materials
ATE544776T1 (de) 1994-12-29 2012-02-15 Massachusetts Inst Technology Chimäre dna-bindeproteine
KR19990022651A (ko) 1995-06-07 1999-03-25 데이비드 엘. 버스테인 생물학적 사건에 대한 라파마이신 기재 조절방법
US6117680A (en) 1997-08-26 2000-09-12 Ariad Gene Therapeutics, Inc. Compositions and methods for regulation of transcription
CA2303482A1 (en) 1997-08-27 1999-03-04 Ariad Gene Therapeutics, Inc. Chimeric transcriptional activators and compositions and uses related thereto
CA2318402A1 (en) 1998-01-15 1999-07-22 Ariad Gene Therapeutics, Inc. Regulation of biological events using multimeric chimeric proteins
AU766513B2 (en) 1998-02-13 2003-10-16 Board Of Trustees Of The Leland Stanford Junior University Novel dimerizing agents, their production and use
PT1916258E (pt) 1999-08-09 2014-07-29 Genzyme Corp Aumento da expressão de uma sequência nucleotídica heteróloga de cadeia simples a partir de vectores virais recombinantes por concepção da sequência de maneira que esta forme pares de bases intracadeia
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
NZ532635A (en) * 2001-11-13 2007-05-31 Univ Pennsylvania A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
EP2278020A3 (en) * 2002-04-09 2011-05-11 Nationwide Children's Hospital, Inc. Antibody gene transfer and recombinant AAV therefor
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
CN1856576B (zh) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US7183969B2 (en) 2004-12-22 2007-02-27 Raytheon Company System and technique for calibrating radar arrays
WO2006110689A2 (en) 2005-04-07 2006-10-19 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
EP1777906A1 (en) 2005-06-09 2007-04-25 Matsushita Electric Industrial Co., Ltd. Amplitude error compensating apparatus and orthogonality error compensating apparatus
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
EP2174667B1 (en) 2007-07-26 2017-01-04 Osaka University Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
EP3257937B1 (en) 2008-02-19 2022-08-03 uniQure IP B.V. Optimisation of expression of parvoviral rep and cap proteins in insect cells
ES2724122T3 (es) 2009-04-30 2019-09-06 Univ Pennsylvania Composiciones para dirigir células de las vías respiratorias de conducción que comprenden construcciones de virus adenoasociado
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
US8628966B2 (en) 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
EP2634253B1 (en) 2010-10-27 2016-05-11 Jichi Medical University Adeno-associated virus virions for transferring genes into neural cells
WO2012109570A1 (en) 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
HRP20171334T1 (hr) 2011-04-22 2017-11-17 The Regents Of The University Of California Virioni adeno-povezanog virusa s kapsid varijantom i postupci njihove upotrebe
ES2857773T5 (es) 2011-08-24 2024-06-04 Univ Leland Stanford Junior Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
US9382319B2 (en) 2011-09-26 2016-07-05 Jn Biosciences Llc Hybrid constant regions
WO2013170078A1 (en) 2012-05-09 2013-11-14 Oregon Health & Science University Adeno associated virus plasmids and vectors
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
EP2970946A4 (en) 2013-03-13 2016-09-07 Philadelphia Children Hospital ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF
KR102413498B1 (ko) 2013-04-20 2022-06-24 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 엑손 2-표적 U7snRNA 폴리뉴클레오티드 작제물의 재조합형 아데노 부속 바이러스 전달
KR20240090694A (ko) 2013-07-22 2024-06-21 더 칠드런스 호스피탈 오브 필라델피아 변종 ａａｖ 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
US9585971B2 (en) 2013-09-13 2017-03-07 California Institute Of Technology Recombinant AAV capsid protein
HUE052676T2 (hu) 2013-10-11 2021-05-28 Massachusetts Eye & Ear Infirmary Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik
WO2015164757A1 (en) 2014-04-25 2015-10-29 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
PE20170261A1 (es) * 2014-05-13 2017-04-12 Univ Pennsylvania Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
BR112017005892A2 (pt) 2014-09-24 2017-12-12 Hope City variantes de vetor de vírus adeno-associado para edição de genoma de alta eficácia e métodos da mesma
CA2981312C (en) 2015-03-30 2023-09-26 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
JP6665466B2 (ja) 2015-09-26 2020-03-13 日亜化学工業株式会社 半導体発光素子及びその製造方法
WO2017070491A1 (en) 2015-10-23 2017-04-27 Applied Genetic Technologies Corporation Ophthalmic formulations
WO2017181021A1 (en) * 2016-04-15 2017-10-19 Regenxbio Inc. Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab
JP7046828B2 (ja) 2016-04-15 2022-04-04 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 滲出型加齢性黄斑変性の治療のための組成物
ES2916344T3 (es) 2016-06-16 2022-06-30 Adverum Biotechnologies Inc Composiciones y métodos para reducir la neovascularización ocular
DK3471780T3 (da) 2016-06-16 2020-11-23 Adverum Biotechnologies Inc Behandling af amd med aav2-variant med aflibercept
WO2018056268A1 (ja) 2016-09-20 2018-03-29 参天製薬株式会社 炎症性眼疾患の治療及び／又は予防剤
CA3040179A1 (en) * 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
AR110074A1 (es) * 2016-11-15 2019-02-20 H Lundbeck As Agentes, usos y métodos para el tratamiento de la sinucleinopatía
BR112019016769A2 (pt) 2017-02-15 2020-05-26 The University Of North Carolina At Chapel Hill Métodos e composições para transferência genética através da vasculatura
AU2018227483A1 (en) 2017-02-28 2019-09-12 Adverum Biotechnologies, Inc. Modified AAV capsids and uses thereof
UY37863A (es) 2017-08-31 2019-03-29 Benitec Biopharma Ltd Virus adenoasociado (aav) con dominio de fosfolipasa modificado
BR112020007405A2 (pt) * 2017-10-18 2020-12-08 Regenxbio Inc. Produtos terapêuticos de anticorpo pós-translacionalmente modificados totalmente humanos
EP3833745A1 (en) * 2018-08-10 2021-06-16 REGENXBIO Inc. Scalable method for recombinant aav production
JP2022514112A (ja) * 2018-10-15 2022-02-09 リジェネクスバイオ インコーポレイテッド 複製欠損型ウイルスベクター及びウイルスの感染性を測定するための方法

Similar Documents

Publication Publication Date Title
JPWO2020219868A5 (https=)
JP7672344B2 (ja) 完全ヒト翻訳後修飾抗体による治療剤
AU2018290885B2 (en) Tropism-modified recombinant viral particles and uses thereof for the targeted introduction of genetic material into human cells
CN101563365B (zh) 抗-il-6单克隆抗体及其用途
US7714119B2 (en) AAV vector compositions and methods for enhanced expression of immunoglobulins using the same
JP7072077B2 (ja) 自己免疫阻害剤及びその適用
CN105669863B (zh) 一种能与人内皮素受体特异性结合的抗体及其应用
JP2023515260A (ja) 抗ヒトインターロイキン－４受容体α抗体及びその調製方法並びに使用
JP5767625B2 (ja) Ｉｌ−１７ｂｒに対する抗体
WO2006129849A1 (ja) 抗ｃｄ１４抗体融合蛋白質
US20210017270A1 (en) Antigen binding proteins to oncostatin m (osm)
CN101491683A (zh) 对阿尔茨海默氏症的新一代基因疗法·免疫疗法的开发
JP2024500115A (ja) 抗体デリバリー
Robert et al. Antibody delivery mediated by recombinant adeno-associated virus for the treatment of various chronic and infectious diseases
AU2024290842A1 (en) Engineered aav capsid proteins
HK1136772A (en) Development of new-generation gene therapy．immunotherapy for alzheimer's disease
HK40103100A (zh) 抗体递送
JPWO2022094106A5 (https=)